【9月16日IPO雷达】建发致新、锦华新材申购、友升股份缴款

Group 1 - The company is planning to issue shares with a subscription code of 301584 at a price of 7.05 yuan, with an earnings per share (EPS) ratio of 13.29 [3] - The company has a total market value that is not specified, indicating potential growth opportunities in the market [3] - The company is backed by the Xiamen State-owned Assets Supervision and Administration Commission, positioning itself as a key player in the high-value medical device distribution sector [4] Group 2 - The company's revenue for 2023 is projected to be 154.4 billion yuan, reflecting a growth of 29.97% compared to 2022 [5] - The revenue forecast for 2024 is 179.2 billion yuan, indicating a year-on-year increase of 16.06% [5] - The company is focusing on upgrading its information systems and investing in new materials, which may enhance operational efficiency and product offerings [5] Group 3 - The company specializes in silane crosslinking agents, with a revenue of 11.15 billion yuan in 2023, showing a growth of 12.13% from the previous year [7] - The projected revenue for 2024 is 12.39 billion yuan, with an expected growth rate of 11.21% [7] - The company is investing in a high-end coupling agent project, which may strengthen its market position in the silane crosslinking agent sector [7] Group 4 - The company has a total market value of 67.13 billion yuan and an earnings per share (EPS) ratio of 22.31 [8] - The company is a supplier of smart distribution equipment and is expected to benefit from deepening relationships with major clients, including China National Petroleum Corporation [8] - The company has established connections with clients in Saudi Arabia, indicating potential for international expansion [8]